GlassScriptPhysician profile
John M Ramsey
NPI 1013558287
$8,203.47
in general payments reported to CMS, 2019-2025
26 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $975 · 2023: $2,760 · 2024: $2,606 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,228.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,568.11 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,138.12 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $794.51 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $771.54 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $472.41 | 2023-2024 | Lybalvi, Aristada |
| Gilead Sciences, INC. | $445.36 | 2023-2025 | Biktarvy, Yeztugo, Descovy |
| Supernus Pharmaceuticals, INC. | $301.67 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $264.74 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $259.44 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $223.48 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $223.35 | 2024 | |
| Tris Pharma INC | $205.19 | 2022-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $195.34 | 2023-2025 | Austedo Xr, Austedo, Uzedy |
| Corium, LLC | $191.40 | 2023-2024 | Azstarys |
| Viiv Healthcare Company | $187.41 | 2025 | Apretude |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $155.06 | 2024-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $153.54 | 2024-2025 | Xelstrym, Secuado |
| Harmony Biosciences LLC | $142.54 | 2023 | Wakix |
| Sunovion Pharmaceuticals INC. | $118.58 | 2022 | |
| Neos Therapeutics, LP | $117.81 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $91.95 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $67.21 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $54.82 | 2024 | Loreev Xr |
| Merck Sharp & Dohme LLC | $25.96 | 2022-2023 | Belsomra |
| Lilly USA, LLC | $17.75 | 2025 | Mounjaro, Zepbound |
| Azurity Pharmaceuticals, INC. | $16.18 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.